Evolus to Report First Quarter 2020 Financial Results and Provide a Business Update on Monday, May 11, 2020
Evolus, Inc. (NASDAQ: EOLS) will release its first quarter 2020 financial results on May 11, 2020, after U.S. market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Evolus, Inc. (NASDAQ: EOLS) will release its first quarter 2020 financial results on May 11, 2020, after U.S. market close. The company, known for its innovative aesthetic product Jeuveau®, invites investors to join a conference call at 4:30 p.m. ET on the same day. Participants can access the call via specific dial-in numbers or through a live audio webcast on Evolus' Investor Relations page. A replay will be available for a limited time post-call. Evolus aims to revolutionize the beauty industry with its customer-centric approach and advanced technology.
Details
News Market Reaction – EOLS
The recorded move for EOLS in the trading session of this news was -1.64%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEWPORT BEACH, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that it will report its first quarter 2020 financial results and provide a business update on Monday, May 11, 2020 after the close of the U.S. financial markets.
Management will host a conference call and live webcast to discuss Evolus’ financial results at 4:30 p.m. ET that same day. A question and answer session will follow management remarks.
The dial-in numbers for the conference call are (866) 916-2317 for domestic callers and (703) 925-2662 for international callers. The conference ID is 1819528.
A replay of the call will be available following its completion through May 18, 2020. To access the replay, dial (855) 859-2056 for domestic callers and (404) 537-3406 for international callers and use the replay conference ID 1819528.
A live audio webcast of the call will be available on the Investor Relations page of the Evolus, Inc. website, https://investors.evolus.com. A replay of the webcast will be archived on Evolus' website for 30 days following the completion of the call.
About Evolus, Inc.
Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus' unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at: http://www.evolus.com.
Jeuveau® is a registered trademark of Evolus, Inc.
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
Evolus, Inc. Contacts:
Investor Contact:
Ashwin Agarwal
Vice President, Finance, Investor Relations & Treasury
Tel: +1-949-284-4559
Email: IR@Evolus.com
Media Contact:
Crystal Muilenburg
Vice President, Corporate Communications & Public Relations
Tel: +1-949-284-4506
Email: media@evolus.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.